Semaglutide Therapy for Alcohol Reduction (STAR)

NCT06015893 on ClinicalTrials.gov · last registry update 2026-09-02

Closed to new participants; the 63 already enrolled are still being followed. Due to report 31 March 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Determine whether semaglutide, compared to placebo, reduces alcohol drinking. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 17 October 2023 — 3 years so far. semaglutide is approved in the US, but not for alcohol use disorder and substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: National Institute on Drug Abuse (NIDA)
Sponsor type: Nih
Enrollment: 63
Started: 2023-10-17
Primary completion: 2027-03-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Determine whether semaglutide, compared to placebo, reduces alcohol drinking.

Conditions studied

Addiction · Alcohol Use Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.